article thumbnail

One shot to stop HIV: MIT's bold vaccine breakthrough

Science Daily: Pharmacology News

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose. By combining two immune-boosting adjuvants alum and SMNP the vaccine lingers in lymph nodes for nearly a month, encouraging the body to produce a vast array of antibodies.

Vaccine 234
article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

He showed that these synthetic CAR T cells could launch an immune response when they encountered the corresponding tumor protein, called CD19. That ability to stick around, which is critical for attacking cancer over time, was another turning point.

Therapies 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ISSUE 44 — The Importance of Cytokine Release Assays to Derisk the Development of Immunomodulatory Drugs

Alta Sciences

One important aspect of toxicity studies is determining whether the drug produces undesired immune effects. The focus is to ensure that the drug does not have any potential to induce an excessive immune response, particularly cytokine storm, which can lead to severe adverse effects and impede clinical development.

article thumbnail

Sanofi Speeds Up Beyfortus Shipments Ahead of 2025-2026 RSV Season

The Pharma Data

According to Thomas Triomphe, Executive Vice President of Vaccines at Sanofi, the product has been administered to over 250,000 infants in real-world settings, backed by more than 40 studies demonstrating its effectiveness in preventing RSV lower respiratory tract disease.

Virus 40
article thumbnail

GSK Licenses Shigella Vaccine Candidate to Bharat Biotech

The Pharma Data

GSK Licenses Shigella Vaccine Candidate to Bharat Biotech in Push for Global Health Equity GSK today announced a significant step forward in the battle against Shigella a leading cause of diarrhoeal disease and death in children under five by licensing its Shigella vaccine candidate, altSonflex1-2-3 , to Bharat Biotech International Limited (BBIL).

article thumbnail

FDA takes major step to ease access to CAR-T therapy

BioPharma Drive: Drug Pricing

For some people with leukemia, lymphoma or multiple myeloma, they can prompt powerful responses and even long-lasting remission. But their administration also comes with notable risks, including a hyperactive immune response known as CRS and neurological toxicity dubbed ICANS.

Therapies 178
article thumbnail

The Ongoing Challenges of Understanding Long COVID and Exploring Innovative Solutions

Perficient: Drug Development

This pattern may relate to differences in immune response, organ-specific vulnerability, or patterns of healthcare utilization. Differential Immune Response: Women with Long COVID typically show higher levels of IL-6 compared to men, particularly those with central sensitization phenotypes.